Update
$Cellectar BioSciences (CLRB.US)$ Cellectar Biosciences’ Iopofosine I 131 Exceeds Primary Endpoint in Waldenstrom’s Macroglobulinemia Pivotal Study With 78% of Major Response Patients Remaining Progression Free at 18 Months
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
steven smith38 : try is this good for us or bad?
Trytosaveabit OP steven smith38 : It’s actually pretty great news! Now have to see how the market reacts? It needs volume! But I’m bullish on it for today, this week? JMO NFA
wwwarrior Trytosaveabit OP : what do you think of SXTP?
Trytosaveabit OP wwwarrior : For me personally, im not interested in it. At least not yet.
wwwarrior Trytosaveabit OP : thanks, that tells me a lot actually coming from you
steven smith38 : try. anything in the ball park . of. 0.00?
Trytosaveabit OP steven smith38 : Not sure what you’re asking? But right now shorts have control along with MM’s routing shares off exchange.